Geron Corporation (GERN)
After hours:
| Previous Close | 4.1500 |
| Open | 4.1600 |
| Bid | 4.2500 x 1800 |
| Ask | 4.2800 x 1800 |
| Day's Range | 4.1500 - 4.3350 |
| 52 Week Range | 1.6400 - 5.3400 |
| Volume | |
| Avg. Volume | 9,012,210 |
| Market Cap | 2.574B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., September 19, 2024--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
FOSTER CITY, Calif., September 09, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron’s global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegle
- Business Wire
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif., August 08, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results and business highlights for the second quarter of 2024.
